Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy
{{output}}
Background: Our phase Ib neoadjuvant trial demonstrated that oncolytic virus (OV) combined with PD-1 blockade achieved a 77.8% pathological response rate and 81.5% 2-year relapse-free survival in patients with acral melanoma. Her... ...
